A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Pyrotinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.
- 07 Jun 2016 Planned number of patients changed from 118 to 128.
- 07 Jun 2016 Status changed from not yet recruiting to active, no longer recruiting.